Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Report Highlights

• Overall, the forecast for Alzheimer's disease, including disease-modifying therapeutics, therapeutics that treat related symptoms, diagnostics and imaging, is set to increase exponentially. This market was worth $8 billion in 2009 and is expected to reach $9.6 billion by 2014, a compound annual growth rate (CAGR) of 3.7%.
  
• Diagnostics and biomarkers are expected to increase at a 5-year compound annual growth rate (CAGR) of nearly 20%. This segment was worth $1.2 billion in 2009 and is expected to reach $2.9 billion by 2014.
  
• The imaging sector was worth $361 million in 2009 and is expected to increase at a nearly 19% compound annual growth rate (CAGR) to reach $852 million in 2014.

INTRODUCTION 

• Examine BCC’s complete catalog of Market Research Reports and place direct orders
• Subscribe to any of BCC’s many industry newsletters
• Read announcements of recently published reports and newly launched newsletters
• Register for BCC’s well-known conferences
• Request additional information on any BCC product
• Take advantage of special offers

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.